Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 602

1.

Interaction proteomics identifies estrogen receptor beta association with multiple chromatin repressive complexes to inhibit cholesterol biosynthesis and exert an oncosuppressive role in triple-negative breast cancer.

Alexandrova E, Giurato G, Saggese P, Pecoraro G, Lamberti J, Ravo M, Rizzo F, Rocco D, Tarallo R, Nyman TA, Collina F, Cantile M, Di Bonito M, Botti G, Nassa G, Weisz A.

Mol Cell Proteomics. 2019 Dec 2. pii: mcp.RA119.001817. doi: 10.1074/mcp.RA119.001817. [Epub ahead of print]

2.

International Expert Panel Consensus on Fat Grafting of the Breast.

Nava MB, Blondeel P, Botti G, Casabona F, Catanuto G, Clemens MW, De Fazio D, De Vita R, Grotting J, Hammond DC, Harris P, Montemurro P, Mendonça Munhoz A, Nahabedian M, Pompei S, Rancati A, Rigotti G, Salgarello M, Scaperrotta G, Spano A, Stan C, Rocco N.

Plast Reconstr Surg Glob Open. 2019 Oct 28;7(10):e2426. doi: 10.1097/GOX.0000000000002426. eCollection 2019 Oct.

3.

Targeting the Formyl Peptide Receptor type 1 to prevent the adhesion of ovarian cancer cells onto mesothelium and subsequent invasion.

Minopoli M, Botti G, Gigantino V, Ragone C, Sarno S, Motti ML, Scognamiglio G, Greggi S, Scaffa C, Roca MS, Stoppelli MP, Ciliberto G, Losito NS, Carriero MV.

J Exp Clin Cancer Res. 2019 Nov 8;38(1):459. doi: 10.1186/s13046-019-1465-8.

4.

Heterogeneity of PD-L1 Expression in Lung Mixed Adenocarcinomas and Adenosquamous Carcinomas.

Zito Marino F, Rossi G, Montella M, Botti G, De Cecio R, Morabito A, La Manna C, Ronchi A, Micheli M, Salatiello G, Micheli P, Rocco D, Accardo M, Franco R.

Am J Surg Pathol. 2019 Oct 29. doi: 10.1097/PAS.0000000000001400. [Epub ahead of print]

PMID:
31688140
5.

Targeting CXCR4 potentiates anti-PD-1 efficacy modifying the tumor microenvironment and inhibiting neoplastic PD-1.

D'Alterio C, Buoncervello M, Ieranò C, Napolitano M, Portella L, Rea G, Barbieri A, Luciano A, Scognamiglio G, Tatangelo F, Anniciello AM, Monaco M, Cavalcanti E, Maiolino P, Romagnoli G, Arra C, Botti G, Gabriele L, Scala S.

J Exp Clin Cancer Res. 2019 Oct 28;38(1):432. doi: 10.1186/s13046-019-1420-8.

6.

Response to "Clarification About 'Expert Consensus on the Use of a New Bioengineered, Cell-Friendly, Smooth Surface Breast Implant'".

Sforza M, Hammond DC, Botti G, Hedén P, Chacón Quirós M, Munhoz AM, Kinney BM, Corduff N.

Aesthet Surg J. 2019 Nov 13;39(12):NP540-NP542. doi: 10.1093/asj/sjz235. No abstract available.

7.

BRAF Mutations and Dysregulation of the MAP Kinase Pathway Associated to Sinonasal Mucosal Melanomas.

Colombino M, Paliogiannis P, Cossu A, De Re V, Miolo G, Botti G, Scognamiglio G, Ascierto PA, Santeufemia DA, Fraggetta F, Manca A, Sini MC, Casula M, Palomba G, Pisano M, Doneddu V, Lissia A, Fedeli MA, Palmieri G.

J Clin Med. 2019 Oct 1;8(10). pii: E1577. doi: 10.3390/jcm8101577.

8.

Drug Release from Pharmaceutical Co-Crystals: Are Therapeutic and Safety Properties of Active Pharmaceutical Substances Retained?

Dalpiaz A, Ferretti V, Botti G, Pavan B.

Curr Drug Deliv. 2019;16(6):486-489. doi: 10.2174/156720181606190723115802.

PMID:
31577199
9.

Correction to: New paradigm for stage III melanoma: from surgery to adjuvant treatment.

Ascierto PA, Borgognoni L, Botti G, Guida M, Marchetti P, Mocellin S, Muto P, Palmieri G, Patuzzo R, Quaglino P, Stanganelli I, Caracò C.

J Transl Med. 2019 Sep 18;17(1):315. doi: 10.1186/s12967-019-2067-0.

10.

Invited Discussion on: "The Importance of Multiple, Different Rhinoplasty Consultations in Patient Selection".

Botti C, Botti G.

Aesthetic Plast Surg. 2019 Dec;43(6):1601-1602. doi: 10.1007/s00266-019-01472-9. Epub 2019 Sep 17. No abstract available.

PMID:
31531698
11.

Cetuximab, irinotecan and fluorouracile in fiRst-line treatment of immunologically-selected advanced colorectal cancer patients: the CIFRA study protocol.

Ottaiano A, Scala S, Normanno N, Napolitano M, Capozzi M, Rachiglio AM, Roma C, Trotta AM, D'Alterio C, Portella L, Romano C, Cassata A, Casaretti R, Silvestro L, Nappi A, Tafuto S, Avallone A, De Stefano A, Tamburini M, Picone C, Petrillo A, Izzo F, Palaia R, Albino V, Amore A, Belli A, Pace U, Di Marzo M, Chiodini P, Botti G, De Feo G, Delrio P, Nasti G.

BMC Cancer. 2019 Sep 9;19(1):899. doi: 10.1186/s12885-019-6109-z.

12.

Impact of ultrasonographic features, cytomorphology and mutational testing on malignant and indeterminate thyroid nodules on diagnostic accuracy of fine needle cytology samples: A prospective analysis of 141 patients.

Fulciniti F, Cipolletta Campanile A, Malzone MG, Chiofalo MG, Capiluongo A, Monaco M, Di Maio N, Sandomenico F, Botti G, Chiappetta G, Vuttariello E, Pezzullo L.

Clin Endocrinol (Oxf). 2019 Dec;91(6):851-859. doi: 10.1111/cen.14089. Epub 2019 Oct 1.

PMID:
31483883
13.

Mutational concordance between primary and metastatic melanoma: a next-generation sequencing approach.

Manca A, Paliogiannis P, Colombino M, Casula M, Lissia A, Botti G, Caracò C, Ascierto PA, Sini MC, Palomba G, Pisano M; Melanoma Unit of Sassari (MUS); Italian Association for Cancer Research (AIRC) Study Group, Doneddu V, Cossu A, Palmieri G; Italian Melanoma Intergroup (IMI).

J Transl Med. 2019 Aug 28;17(1):289. doi: 10.1186/s12967-019-2039-4.

14.

Pembrolizumab in lung cancer: current evidence and future perspectives.

Palumbo G, Carillio G, Manzo A, Montanino A, Sforza V, Costanzo R, Sandomenico C, Manna C, Luca G, Piccirillo MC, Daniele G, Cecio R, Botti G, Totaro G, Muto P, Picone C, Esposito G, Normanno N, Morabito A.

Future Oncol. 2019 Oct;15(29):3327-3336. doi: 10.2217/fon-2019-0073. Epub 2019 Aug 21.

PMID:
31432705
15.

New paradigm for stage III melanoma: from surgery to adjuvant treatment.

Ascierto PA, Borgognoni L, Botti G, Guida M, Marchetti P, Mocellin S, Muto P, Palmieri G, Patuzzo R, Quaglino P, Stanganelli I, Caracò C.

J Transl Med. 2019 Aug 14;17(1):266. doi: 10.1186/s12967-019-2012-2. Review. Erratum in: J Transl Med. 2019 Sep 18;17(1):315.

16.

Dissecting the prevention of estrogen-dependent breast carcinogenesis through Nrf2-dependent and independent mechanisms.

Giudice A, Barbieri A, Bimonte S, Cascella M, Cuomo A, Crispo A, D'Arena G, Galdiero M, Della Pepa ME, Botti G, Caraglia M, Capunzo M, Arra C, Montella M.

Onco Targets Ther. 2019 Jun 24;12:4937-4953. doi: 10.2147/OTT.S183192. eCollection 2019. Review.

17.

Paracrine recruitment and activation of fibroblasts by c-Myc expressing breast epithelial cells through the IGFs/IGF-1R axis.

De Vincenzo A, Belli S, Franco P, Telesca M, Iaccarino I, Botti G, Carriero MV, Ranson M, Stoppelli MP.

Int J Cancer. 2019 Nov 15;145(10):2827-2839. doi: 10.1002/ijc.32613. Epub 2019 Aug 23.

PMID:
31381136
18.

Developmental Gene Markers in Tumor Pathogenesis and Progression.

Cantile M, Palmieri G, Botti G.

Dis Markers. 2019 Jul 8;2019:5462562. doi: 10.1155/2019/5462562. eCollection 2019. No abstract available.

19.

The Oncolytic Virus dl922-947 Triggers Immunogenic Cell Death in Mesothelioma and Reduces Xenograft Growth.

Di Somma S, Iannuzzi CA, Passaro C, Forte IM, Iannone R, Gigantino V, Indovina P, Botti G, Giordano A, Formisano P, Portella G, Malfitano AM, Pentimalli F.

Front Oncol. 2019 Jul 12;9:564. doi: 10.3389/fonc.2019.00564. eCollection 2019.

20.

Diagnostic performance of gadoxetic acid-enhanced liver MRI versus multidetector CT in the assessment of colorectal liver metastases compared to hepatic resection.

Granata V, Fusco R, de Lutio di Castelguidone E, Avallone A, Palaia R, Delrio P, Tatangelo F, Botti G, Grassi R, Izzo F, Petrillo A.

BMC Gastroenterol. 2019 Jul 24;19(1):129. doi: 10.1186/s12876-019-1036-7.

21.

CXCL12 loaded-dermal filler captures CXCR4 expressing melanoma circulating tumor cells.

Ieranò C, D'Alterio C, Giarra S, Napolitano M, Rea G, Portella L, Santagata A, Trotta AM, Barbieri A, Campani V, Luciano A, Arra C, Anniciello AM, Botti G, Mayol L, De Rosa G, Pacelli R, Scala S.

Cell Death Dis. 2019 Jul 22;10(8):562. doi: 10.1038/s41419-019-1796-6.

22.

Perspectives in melanoma: meeting report from the Melanoma Bridge (November 29th-1 December 1st, 2018, Naples, Italy).

Ascierto PA, Agarwala SS, Botti G, Budillon A, Davies MA, Dummer R, Ernstoff M, Ferrone S, Formenti S, Gajewski TF, Garbe C, Hamid O, Lo RS, Luke JJ, Michielin O, Palmieri G, Zitvogel L, Marincola FM, Masucci G, Caracò C, Thurin M, Puzanov I.

J Transl Med. 2019 Jul 22;17(1):234. doi: 10.1186/s12967-019-1979-z.

23.

Semiclassical vibrational spectroscopy with Hessian databases.

Conte R, Gabas F, Botti G, Zhuang Y, Ceotto M.

J Chem Phys. 2019 Jun 28;150(24):244118. doi: 10.1063/1.5109086.

24.

Response to "Is There a Role for a Noninvasive Alternative to Face and Neck Lifting? The Polydioxanone Thread Lift".

Bertossi D, Botti G, Gualdi A, Fundarò P, Nocini R, Pirayesh A, van der Lei B.

Aesthet Surg J. 2019 Jul 12;39(8):364-365. doi: 10.1093/asj/sjz150. No abstract available.

PMID:
31216003
25.

LncRNA HOTAIR up-regulation is strongly related with lymph nodes metastasis and LAR subtype of Triple Negative Breast Cancer.

Collina F, Aquino G, Brogna M, Cipolletta S, Buonfanti G, De Laurentiis M, Di Bonito M, Cantile M, Botti G.

J Cancer. 2019 May 12;10(9):2018-2024. doi: 10.7150/jca.29670. eCollection 2019.

26.

AXL Is a Novel Predictive Factor and Therapeutic Target for Radioactive Iodine Refractory Thyroid Cancer.

Collina F, La Sala L, Liotti F, Prevete N, La Mantia E, Chiofalo MG, Aquino G, Arenare L, Cantile M, Liguori G, Di Gennaro F, Pezzullo L, Losito NS, Vecchio G, Botti G, Melillo RM, Franco R.

Cancers (Basel). 2019 Jun 7;11(6). pii: E785. doi: 10.3390/cancers11060785.

27.

Cardiotoxicity and pro-inflammatory effects of the immune checkpoint inhibitor Pembrolizumab associated to Trastuzumab.

Quagliariello V, Passariello M, Coppola C, Rea D, Barbieri A, Scherillo M, Monti MG, Iaffaioli RV, De Laurentiis M, Ascierto PA, Botti G, De Lorenzo C, Maurea N.

Int J Cardiol. 2019 Oct 1;292:171-179. doi: 10.1016/j.ijcard.2019.05.028. Epub 2019 May 17.

PMID:
31160077
28.

Paralogous HOX13 Genes in Human Cancers.

Botti G, Cillo C, De Cecio R, Malzone MG, Cantile M.

Cancers (Basel). 2019 May 20;11(5). pii: E699. doi: 10.3390/cancers11050699. Review.

29.

Automatic discovery of image-based signatures for ipilimumab response prediction in malignant melanoma.

Harder N, Schönmeyer R, Nekolla K, Meier A, Brieu N, Vanegas C, Madonna G, Capone M, Botti G, Ascierto PA, Schmidt G.

Sci Rep. 2019 May 15;9(1):7449. doi: 10.1038/s41598-019-43525-8.

30.

Drug release from pharmaceutical co-crystals: are therapeutic and safety properties of active pharmaceutical substances retained?

Dalpiaz A, Ferretti V, Botti G, Pavan B.

Curr Drug Deliv. 2019 May 13. doi: 10.2174/1567201816666190514101303. [Epub ahead of print] No abstract available.

PMID:
31084593
31.

LncRNA HOTAIR in Tumor Microenvironment: What Role?

Botti G, Scognamiglio G, Aquino G, Liguori G, Cantile M.

Int J Mol Sci. 2019 May 8;20(9). pii: E2279. doi: 10.3390/ijms20092279. Review.

32.

Oral lichen planus and other confounding factors in narrow band imaging (NBI) during routine inspection of oral cavity for early detection of oral squamous cell carcinoma: a retrospective pilot study.

Guida A, Maglione M, Crispo A, Perri F, Villano S, Pavone E, Aversa C, Longo F, Feroce F, Botti G, Ionna F.

BMC Oral Health. 2019 Apr 30;19(1):70. doi: 10.1186/s12903-019-0762-0.

33.

Noncoding RNAs as circulating biomarkers in osteosarcoma patients.

Botti G, Giordano A, Feroce F, De Chiara AR, Cantile M.

J Cell Physiol. 2019 Nov;234(11):19249-19255. doi: 10.1002/jcp.28744. Epub 2019 Apr 29. Review.

PMID:
31032924
34.

Correction: Nine-year distribution pattern of hepatitis C virus (HCV) genotypes in Southern Italy.

Petruzziello A, Sabatino R, Loquercio G, Guzzo A, Di Capua L, Labonia F, Cozzolino A, Azzaro R, Botti G.

PLoS One. 2019 Apr 12;14(4):e0215559. doi: 10.1371/journal.pone.0215559. eCollection 2019.

35.

Expert Consensus on the Use of a New Bioengineered, Cell-Friendly, Smooth Surface Breast Implant.

Sforza M, Hammond DC, Botti G, Hedén P, Chacón Quirós M, Munhoz AM, Kinney BM, Corduff N.

Aesthet Surg J. 2019 Apr 8;39(Supplement_3):S95-S102. doi: 10.1093/asj/sjz054.

36.

Boswellic acid has anti-inflammatory effects and enhances the anticancer activities of Temozolomide and Afatinib, an irreversible ErbB family blocker, in human glioblastoma cells.

Barbarisi M, Barbarisi A, De Sena G, Armenia E, Aurilio C, Libutti M, Iaffaioli RV, Botti G, Maurea N, Quagliariello V.

Phytother Res. 2019 Jun;33(6):1670-1682. doi: 10.1002/ptr.6354. Epub 2019 Mar 28.

PMID:
30924205
37.

Low doses of Bisphenol A have pro-inflammatory and pro-oxidant effects, stimulate lipid peroxidation and increase the cardiotoxicity of Doxorubicin in cardiomyoblasts.

Quagliariello V, Coppola C, Mita DG, Piscopo G, Iaffaioli RV, Botti G, Maurea N.

Environ Toxicol Pharmacol. 2019 Jul;69:1-8. doi: 10.1016/j.etap.2019.03.006. Epub 2019 Mar 7.

PMID:
30903913
38.

18F-FDG PET/CT Is an Early Predictor of Pathologic Tumor Response and Survival After Preoperative Radiochemotherapy with Bevacizumab in High-Risk Locally Advanced Rectal Cancer.

Avallone A, Aloj L, Pecori B, Caracò C, De Stefano A, Tatangelo F, Silvestro L, Granata V, Bianco F, Romano C, Di Gennaro F, Budillon A, Petrillo A, Muto P, Botti G, Delrio P, Lastoria S.

J Nucl Med. 2019 Nov;60(11):1560-1568. doi: 10.2967/jnumed.118.222604. Epub 2019 Mar 15.

PMID:
30877175
39.

"Dynamic Canthopexy" Drill Hole Canthal Repositioning.

Botti G, Botti C, Rossati L, Gualdi A, Nocini P, Nocini R, Bertossi D.

Aesthet Surg J. 2019 Nov 13;39(12):1284-1294. doi: 10.1093/asj/sjz077.

PMID:
30874720
40.

Multimodal approaches and tailored therapies for pain management: the trolley analgesic model.

Cuomo A, Bimonte S, Forte CA, Botti G, Cascella M.

J Pain Res. 2019 Feb 19;12:711-714. doi: 10.2147/JPR.S178910. eCollection 2019.

41.

The Presence of Concomitant Mutations Affects the Activity of EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) Patients.

Rachiglio AM, Fenizia F, Piccirillo MC, Galetta D, Crinò L, Vincenzi B, Barletta E, Pinto C, Ferraù F, Lambiase M, Montanino A, Roma C, Ludovini V, Montagna ES, De Luca A, Rocco G, Botti G, Perrone F, Morabito A, Normanno N.

Cancers (Basel). 2019 Mar 10;11(3). pii: E341. doi: 10.3390/cancers11030341.

42.

Prevalence of Hepatitis C virus genotypes in nine selected European countries: A systematic review.

Petruzziello A, Loquercio G, Sabatino R, Balaban DV, Ullah Khan N, Piccirillo M, Rodrigo L, di Capua L, Guzzo A, Labonia F, Botti G.

J Clin Lab Anal. 2019 Jun;33(5):e22876. doi: 10.1002/jcla.22876. Epub 2019 Mar 7.

43.

Nine-year distribution pattern of hepatitis C virus (HCV) genotypes in Southern Italy.

Petruzziello A, Sabatino R, Loquercio G, Guzzo A, Di Capua L, Labonia F, Cozzolino A, Azzaro R, Botti G.

PLoS One. 2019 Feb 20;14(2):e0212033. doi: 10.1371/journal.pone.0212033. eCollection 2019. Erratum in: PLoS One. 2019 Apr 12;14(4):e0215559.

44.

Costs of clinical trials with anticancer biological agents in an Oncologic Italian Cancer Center using the activity-based costing methodology.

Pascarella G, Capasso A, Nardone A, Triassi M, Pignata S, Arenare L, Ascierto P, Curvietto M, Maiolino P, D'Aniello R, Montanino A, Laudato F, De Feo G, Botti G, Perrone F, Petrillo A, Cavalcanti E, Lastoria S, Maurea N, Morabito A.

PLoS One. 2019 Jan 8;14(1):e0210330. doi: 10.1371/journal.pone.0210330. eCollection 2019.

45.

Posterior HOX genes and HOTAIR expression in the proximal and distal colon cancer pathogenesis.

Tatangelo F, Di Mauro A, Scognamiglio G, Aquino G, Lettiero A, Delrio P, Avallone A, Cantile M, Botti G.

J Transl Med. 2018 Dec 12;16(1):350. doi: 10.1186/s12967-018-1725-y.

46.

PD-L1 expression with immune-infiltrate evaluation and outcome prediction in melanoma patients treated with ipilimumab.

Madonna G, Ballesteros-Merino C, Feng Z, Bifulco C, Capone M, Giannarelli D, Mallardo D, Simeone E, Grimaldi AM, Caracò C, Botti G, Fox BA, Ascierto PA.

Oncoimmunology. 2018 Sep 5;7(12):e1405206. doi: 10.1080/2162402X.2017.1405206. eCollection 2018.

47.

Mutated Von Hippel-Lindau-renal cell carcinoma (RCC) promotes patients specific natural killer (NK) cytotoxicity.

Trotta AM, Santagata S, Zanotta S, D'Alterio C, Napolitano M, Rea G, Camerlingo R, Esposito F, Lamantia E, Anniciello A, Botti G, Longo N, Botti G, Pignata S, Perdonà S, Scala S.

J Exp Clin Cancer Res. 2018 Dec 4;37(1):297. doi: 10.1186/s13046-018-0952-7.

48.

AMBRA1 Controls Regulatory T-Cell Differentiation and Homeostasis Upstream of the FOXO3-FOXP3 Axis.

Becher J, Simula L, Volpe E, Procaccini C, La Rocca C, D'Acunzo P, Cianfanelli V, Strappazzon F, Caruana I, Nazio F, Weber G, Gigantino V, Botti G, Ciccosanti F, Borsellino G, Campello S, Mandolesi G, De Bardi M, Fimia GM, D'Amelio M, Ruffini F, Furlan R, Centonze D, Martino G, Braghetta P, Chrisam M, Bonaldo P, Matarese G, Locatelli F, Battistini L, Cecconi F.

Dev Cell. 2018 Dec 3;47(5):592-607.e6. doi: 10.1016/j.devcel.2018.11.010.

PMID:
30513302
49.

Abandoned frozen embryos in Argentina: a committee opinion.

Lima NS, Botti G, Lancuba S, Martínez AG.

JBRA Assist Reprod. 2019 Apr 30;23(2):165-168. doi: 10.5935/1518-0557.20180085.

50.

Overexpression of ADAR1 into the cytoplasm correlates with a better prognosis of patients with oral squamous cells carcinoma.

Caponio VCA, Troiano G, Botti G, Pedicillo MC, Lo Russo L, Mastrangelo F, Ciavarella D, Losito NS, Aquino G, Nocini R, Santoro R, Santoro A, Lo Muzio L, Pannone G.

J Oral Pathol Med. 2019 Feb;48(2):108-114. doi: 10.1111/jop.12808. Epub 2018 Dec 16.

PMID:
30489667

Supplemental Content

Support Center